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Abstract
Currently, the development of effective diagnostic reagents as well as treatments against Hepatitis C virus (HCV) remains a
high priority. In this study, we have described the development of an alive cell surface -Systematic Evolution of Ligands by
Exponential Enrichment (CS-SELEX) technique and screened the functional ssDNA aptamers that specifically bound to HCV
envelope surface glycoprotein E2. Through 13 rounds of selection, the CS-SELEX generated high-affinity ssDNA aptamers,
and the selected ssDNA aptamer ZE2 demonstrated the highest specificity and affinity to E2-positive cells. HCV particles
could be specifically captured and diagnosed using the aptamer ZE2. A good correlation was observed in HCV patients
between HCV E2 antigen-aptamer assay and assays for HCV RNA quantities or HCV antibody detection. Moreover, the
selected aptamers, especially ZE2, could competitively inhibit E2 protein binding to CD81, an important HCV receptor, and
significantly block HCV cell culture (HCVcc) infection of human hepatocytes (Huh7.5.1) in vitro. Our data demonstrate that
the newly selected ssDNA aptamers, especially aptamer ZE2, hold great promise for developing new molecular probes, as
an early diagnostic reagent for HCV surface antigen, or a therapeutic drug specifically for HCV.
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Introduction
Hepatitis C virus (HCV) is estimated to have infected 3% of the
world’s population (approximately 170 million people). Approx-
imately 80% of the infected patients develop liver cirrhosis and, in
some cases, hepatocarcinoma [1,2]. Recent reports have shown
more HCV recurrence and decreased survival for HCV following
orthotopic liver transplantation or insulin resistance in patients
with chronic hepatitis C [3,4]. In addition, there is a high
prevalence of HCV, HIV, and hepatitis B virus (HBV) coinfection,
which requires that the access to diagnosis and therapies for these
infections is improved. Presently, the only available therapy is
alpha interferon (IFN-a) alone or in combination with ribavirin
[5–7]. Such treatments are expensive, show low response rates,
and carry the risk of significant side effects [6–8]. Effective
therapies to counteract this important public health problem are
still lacking.
Early diagnosis of HCV infection in HCV- or HIV-infected
patients has significant implications for patient management.
However, the currently recommended serological screening
strategy for identifying anti-HCV antibodies is unable to detect
plasma donations that are anti-HCV-negative and HCV RNA-
positive during the pre-seroconversion window period (PWP).
Another method for detecting HCV RNA is reverse transcript
polymerase chain reaction (RT-PCR), which is not feasible due to
its high cost; it is not used routinely in the diagnostic laboratories,
especially in developing countries [9,10]. The latest breakthrough
in diagnosing early HCV infection is by detecting the HCV
core antigen that is present during the early stage or before
seroconversion [11]. However, relying solely on a single HCV core
antigen assay may not be useful for a definite diagnosis of early
HCV infection. None of the current methods are available to
measure the HCV surface antigens in serum. More sensitive and
less expensive assays for the early diagnosis of HCV are needed.
HCV is a member of the Flaviviridae family and is an enveloped
virus with a single-stranded RNA genome approximately 9.5 kb in
length that contains a single open reading frame [12–14]. The
open reading frame encodes a polyprotein of approximately 3,010
amino acids that is processed into at least 10 mature proteins (C,
E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) by both
host signal peptidases and viral proteases. HCV contains two
heavily glycosylated envelope glycoproteins, E1 and E2. E2 is
thought to initiate viral attachment [15], whereas E1 may be
involved in virus-cell membrane fusion. The envelope E2
glycoprotein plays a critical role in the initiating infection through
recognizing and binding to human cellular receptors [16–20]. It
has been proposed that the E2 glycoprotein binds to CD81, a
tetraspanin molecule that is expressed on hepatocytes and B
lymphocytes. HCV infection is dependent on at least three co-
receptors: CD81, scavenger receptor BI (SR-BI), and claudin-1
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8142[16–20]. Among them, CD81 has been identified as a critical co-
receptor for HCV particle entry [16–20].
High affinity aptamers for specific target molecules can be
isolated from a library of randomized sequences in vitro using the
SELEX (systematic evolution of ligands by exponential enrich-
ment) process [21]. SELEX involves sequential rounds of selection
and amplification from a vast pool of nucleic acids (10
14 molecules)
for ligands (aptamers) that bind with high affinity to target
molecules. Aptamers are short, single-stranded oligonucleotides
that can fold into specific three-dimensional structures in order to
recognize target molecules, such as small chemicals, proteins, or
even cells; as such, they have several potential advantages over
antibodies and antibiotics. Being smaller than antibodies,
aptamers are better candidates for cell penetration and blood
clearance. Aptamers have been used for pure recognition,
inhibition, diagnostic, and therapeutic applications [21].
Small aptamers that inhibit the virus at the stage of viral entry
(e.g., by blocking the interactions between the viral envelope
glycoprotein and the cellular receptor or co-receptor) have not
been described so far. Several aptamers have been selected against
HCV [22–24]. However, none of these have been selected against
surface envelope glycoproteins. Currently, few SELEX strategies
exist to generate inhibitors against glycosylated viral envelope
proteins.
In the present study, we developed a new SELEX procedure
termed alive cell surface-SELEX (CS-SELEX), which targets the
E2 envelope glycoprotein expressed on the mammalian cell line
CT26. In this model system, we carried out CS-SELEX by
establishing a stable cell line that ectopically expressed the HCV
E2 glycoprotein on the cell surface and examined the binding
affinities and functions of selected ssDNA aptamers.
Results
High-affinity Aptamers for HCV-E2 Glycoprotein Were
Isolated by CS-SELEX
To isolate aptamers that specifically bind to the HCV E2
envelope glycoprotein, we utilized E2-expressing CT26 cells as a
selection target; CT26 cells were used for counter selection. Our
approach relies on CS-SELEX to evolve aptamers for whole live
cells that express a variety of surface markers representing
molecular differences among E2-CT26 cells and CT26 cells.
The random ssDNA library (ca.10
14 molecules) was used to screen
ligands that bind to E2-CT26 cells (Fig. 1A). Aptamers that bind to
E2-CT26 cells with high affinity and specificity were successfully
obtained.
After 14 rounds of selection, different pools of aptamers were
obtained using CS-SELEX, and the binding affinities between
aptamers and E2-CT26 cells were measured by flow cytometry as
described in the Methods. The sequence of binding affinities
between FITC-labeled aptamers was as follows: 13
th Pool.12
th
Pool.10
th Pool.14
th Pool.1
st Pool, as shown in Figs. 1B and 1C.
The 13
thPool clones were cloned into pUC19, and individual clones
of single aptamers were selected and sequenced. The consensus regions
within the individual aptamers are shown in Table 1. The single
aptamer ZE2 has the highest binding affinity among all aptamers with
aK do f1 . 0 5 61n M .T h es e q u e n c eo fb i n d i n ga f f i n i t i e sw a sa sf o l l o w s :
ZE2 (Kd 1.0561n M ) .13
th P (Kd 1.6760.9 nM).ZE3 (Kd
3.2260.7 nM).12
th P (Kd 6.3460.9 nM).ZE5 (Kd 4.2960.6 nM)
.ZE4 (Kd 8.8561n M ) .10
th P (Kd 16.666 nM) (Table 2).
The SsDNA Aptamer ZE2 with the Highest Binding
Affinity Specifically Targets HCV E2
The single aptamer ZE2 was chosen for further characteriza-
tion, as it had the highest E2 binding affinity. Firstly, the
interaction between the ssDNA aptamer ZE2 and the E2 protein
was demonstrated by capillary zone electrophoresis. The GST-E2
and GST recombinant proteins were purified and confirmed using
SDS-PAGE and western blot analysis (Fig. 2A). The capillary
electrophoresis method is based on simple UV detection at
260 nm with a linear polymer buffer and a coated capillary; it
requires no labeling or derivatization of the DNA. We observed
that the DNA aptamer ZE2 was facilely adsorbed to the GST-E2
protein but not to the GST protein (Fig. 2C), and the binding was
completed within 10 min. A specific E2 protein-DNA aptamer
ZE2 complex was observable as a retarded peak, which increased
Figure 1. High-affinity aptamers for HCV-E2 glycoprotein were isolated by CS-SELEX. (A) The E2 stably expressing cell line E2-CT26 was
established, and E2-CT26 E2 cell surface expression was identified by a PE-conjugated anti-E2 antibody using flow cytometry. (B) Comparison of
binding percentages of different pools of FITC-labeled aptamers with E2-CT26 cells using flow cytometry. Data shown were calculated as mean6SEM,
and data are from three independent experiments. (C) Representative results from different pools of FITC-labeled aptamers binding with E2-CT26
cells by flow cytometry.
doi:10.1371/journal.pone.0008142.g001
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reduction in the free DNA peak (Fig. 2B).
Fluorescence Microscope Imaging of E2-expressing Cells
with FITC-ZE2 Aptamer
The secondary structure of the ssDNAaptamer ZE2 was predicted
with the DNAMANsoftware (Lynnon Biosoft), and it showed that the
terminal loop of a stem-loop structure might be the site of binding to
the target E2 protein (Fig. 3A). To test this possibility, a ssDNA
aptamer ZE2-mutwassynthesized, inwhichtwobasesintheterminal
loop of a stem-loop structure of ZE2 were mutated (Fig. 3A). We
further observed that E2-expressing cells, E2-HepG2, specifically
bound FITC-ZE2 aptamers under the fluorescence microscope
(Figs. 3B and 3C). The fluorescence intensities of the binding affinities
between FITC-ZE2 and E2-expressing cells were aptamer dose-
dependent (Fig. 3C), and a much smaller fluorescence intensity was
observed when using the FITC-ZE2-mut (Fig. 3C). Similar results
were observed for fluorescence microscope imaging of E2-CT26 cells
bound with the FITC-ZE2 aptamer (data not shown). No binding
between FITC-ZE2 and HepG2or CT26 cells was detected (Figs. 3B
and 3C).
The above data suggest that the ssDNA aptamer ZE2
specifically targets HCV envelope glycoprotein E2-expressing
cells, and FITC-ZE2 can be used as a probe to detect E2-
expressing cells using a fluorescence microscope.
The ssDNA Aptamer ZE2 Specifically Targets HCV Particles
To determine whether this selected aptamer ZE2 could bind to
HCV particles, virus capture assays were performed by sandwich
ELISA. Virus samples from HCVcc were incubated in the anti-E2
polyclonal antibody-precoated ELISA plates. Biotin-aptamers were
then added and incubated,followed byextensivewashingtoremove
unbound aptamers. The bound viral particles were revealed by the
biotin-labeled aptamers as described in the Materials and Methods.
We found that ZE2 aptamer binding to the HCV particles was
aptamer dose-dependent, but the ZE3 aptamer or the ZE2-mut
with two mutated bases had a much lower binding affinity (Fig. 4A).
These results are consistent with their binding affinities with E2
glycoprotein. No binding was observed between the ZE2 aptamer
and control culture media (Fig. 4A).
In addition, sera samples from 154 Chinese HCV patients (both
HCV antibody- and HCV RNA-positive) and 155 healthy donors
(both HCV antibody- and HCV RNA- negative) were collected
and measured using the biotin-ZE2 probe with sandwich ELISA.
As shown in Table 3 and Fig. 4B, a good correlation was observed
between HCV E2 antigen-aptamer assay and assays for HCV
RNA quantities or HCV antibody detection. Biotin-labeled ZE2
could bind to HCV particles in HCV patient samples with much
higher affinities than to healthy donor samples (* p,0.05, Table 3,
Fig. 4B), and the absorbance values of the HCV serum samples
were not only proportional to serial dilutions of sera, but also to
HCV RNA copies measured by RT-PCR (Fig. 4B).
These data suggest that the ssDNA aptamer ZE2 specifically
targets HCV particles and could be used to diagnose early HCV
infection by detecting HCV surface antigen in sera that is present
during the early stage or before seroconversion.
Genotypes 1a, 1b, and 2a of E2 Can be Significantly
Captured by Aptamer ZE2
HCV has six major genotypes and numerous subtypes based on its
positive-strand RNA genome, and a seventh major genotype was
recently discovered [25]. E1E2 gene (from genotypes 1 to 6) stable-
expressing HepG2 cells were established by G418 selection, and E2
expressions from these cells were determined by western blot analysis
(Fig. 4C). Different genotypes of E1E2 gene stable-expressing HepG2
cellswereusedtocoatELISAplates.WeutilizedELISAtodetermine
which genotypes of E1E2 could be bound by ZE2. The results
showed that aptamer ZE2 was specifically targeted to the E2 proteins
of genotypes 1a, 1b, and 2a, and the binding affinities of aptamer ZE2
with genotypes 1a, 1b, and 2a of E2 were three to five-fold higher
than those of genotypes 3, 4, 5, and 6 (Fig. 4D).
Selected Aptamers Block E2 Protein Binding to Target
Huh7.5.1 Cells
As the aptamer ZE2 specifically binds to HCV E2, we next further
determined whether aptamer ZE2 also has the ability to block HCV
E2 binding to its target cells. Human hepatocyte Huh7.5.1 cells are
supposed to express the HCV E2-binding receptor CD81, and
human CD81 has been described as a main receptor for HCV (16–
20). We used a PE-labeled anti-CD81 antibody to detect whether
Huh7.5.1 cells expressed CD81. A flow cytometric analysis showed
that PE-labeled anti-CD81 antibody bound to Huh7.5.1 cells with a
much higher binding affinity than that of the PE-labeled control
antibody (Ab) (Fig. 5A). When the E2 or GST proteins were added,
Huh7.5.1 cells significantly bound to the E2 protein (Fig. 5B), and
their binding affinities were much higher than they were for the
control GST protein (Fig. 5B, * p,0.05). The E2 protein specifically
b o u n dt oH u h 7 . 5 . 1c e l l sb u tn o tt oC T 2 6c e l l s( F i g .5 B ) .A l lo ft h e
above data suggest that Huh7.5.1 cellular surfaces have HCV E2-
binding CD81 receptor molecules.
Table 2. Binding affinities or Kd values of different aptamers.
Aptamers 4
th P1 0
th P1 2
th P1 3
th P1 4
th P ZE2 ZE3 ZE5
Kd (nM) 51.467 16.666 6.3465.5 1.6760.9 50.3613 1.0560.4 3.2260.7 4.2960.6
‘‘P’’ represents pool; ZE2, ZE3, and ZE5 are different single aptamers from the 13th pool.
doi:10.1371/journal.pone.0008142.t002
Table 1. Consensus regions within the representive
individual aptamers are underlined or shaded.
Aptamer Frequency ssDNA aptamer sequences (N30)
ZE1 1/8 ATAGGGCACTTGTC CTCACACCACGGTGTGA
ZE2 2/8 GAATGAGGAATAATCTAGCTCCTTCGCTGA
ZE3 2/8 CGCCGTATTAAGATTGGGAGACCTGGTAGA
ZE4 1/8 GGGCCTCGATTTAGTTCGCGGCCATAGGGC
ZE5 1/8 TCCATTCATGTAACGAACATAGTTTTGGCA
ZE6 1/8 AGTTCGACTCCGTTAGGTGTCGCTGTAGGT
Consensus -A-T----T-
doi:10.1371/journal.pone.0008142.t001
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aptamers significantly blocked HCV E2 protein binding to
Huh7.5.1 cells (Fig. 5C). The sequence of inhibition effects was
as follows: ZE2.13
th P.6
Th P (Fig. 5B). The inhibitory effects of
the aptamers were consistent with their binding affinity results
shown in Table 1. However, GST and ZE2 had no significant
binding affinities for Huh7.5.1 cells (Fig. 5D). The recombinant
CD81 protein could competitively inhibit the aptamers from
binding to the E2-expressing cells (E2-CT26), especially ZE2 and
the 13
th pool aptamers (Fig. 5E), while no or weak inhibitory
effects were observed for the 4
th and 12
th pool aptamers (Fig. 5E),
which due to their less binding affinities to E2 comparing the 13
th
pool aptamers and ZE2 aptamer (Table 2). Moreover, ZE2 or
CD81 blocked approximately 80% of HCV E2 protein binding to
CD81-expressing Huh7.5.1 cells, respectively (Fig. 5F). The
addition of both ZE2 and CD81 blocked approximately 90% of
HCV E2 protein binding to Huh7.5.1 cells (Fig. 5F). All of these
data indicate that ZE2 and CD81 may share similar binding sites
on HCV E2 and that aptamer ZE2 can block HCV E2 binding to
target Huh7.5.1 cells.
Aptamer ZE2 Dramatically Inhibits HCV Infection of
Huh7.5.1 Cells
Finally, we examined the inhibitory effects of aptamer ZE2 on
HCV infection of human hepatocyte Huh7.5.1 cells. Immuno-
fluorescence microscopy demonstrated that the mean fluores-
cence intensities (MFIs) of intracellular HCV were significantly
decreased upon the addition of the ZE2 aptamer or IFN-a
(Fig. 6A). While the ZE2-mut and ZE3 had lower inhibitory
effects on viral infection compared to ZE2 (Fig. 6A). These results
are consistent with their binding affinities with E2 glycoprotein.
The intracellular HCV E2 protein and viral RNA levels were
further determined by western blotting (Fig. 6B) and real-time
RT-PCR analysis, respectively (Fig. 6C). Both the western blot
and real-time RT-PCR showed that there was a dose-dependent
inhibitory effect of the aptamer ZE2 on viral infection, and the
inhibitory effect of 100 nM ZE2 aptamer was virtually equivalent
to that of 500 IU IFN-a (Figs. 6B and 6C). These data illustrate
that aptamer ZE2 may indeed block and inhibit viral infection of
human hepatocytes.
Discussion
This study shows that the ssDNA aptamers that bind specifically
to HCV-E2 have been successfully generated by CS-SELEX for
the first time. In contrast to most described SELEX methods, our
approach relies on CS-SELEX to evolve aptamers for whole live
cells that express a variety of surface markers representing
molecular differences among different cells. The aptamers selected
from CS-SELEX for whole live cells have much higher specificity
than those aptamers from SELEX for a single target molecule.
Most importantly, the aptamers we selected here bound to the
natural form of the E2 envelope glycoprotein expressed on the
mammalian CT26 cells, with glycosylation modifications that can
affect protein folding, structure, and function. In addition, our
approach involves DNA aptamers, which present several advan-
tages over RNA aptamers, such as their increased stability, long
shelf-life, and ease of chemical synthesis in large quantities at a
relatively low cost.
Our finding firstly identified that the ZE2 ssDNA aptamer was
able to identify the presence of HCV E2 surface antigen or free E2
antigen in HCV patient serum samples by a simple ELISA
method. This method was highly consistent with the detectable
results of HCV antibody and HCV RNA of HCV patient serum
samples (Table 3, Fig. 4B). These data suggest that the ssDNA
aptamer ZE2 could be used to diagnose early HCV infection by
detecting the HCV surface antigen that is present in sera during
the early stage of infection or before seroconversion. Furthermore,
the ssDNA aptamer ZE2 could specifically target HCV envelope
glycoprotein E2-expressing cells (Figs. 3B and 3C), and FITC-ZE2
seemed to be promising as a probe to detect HCV-infected cells.
Such technology could be used both in vitro and in vivo for animal
experiments in concert with fluorescence microscopy and optical in
vivo imaging technology, respectively.
The limitations of the detection of anti-HCV antibodies or
HCV RNA in serum currently used for the diagnosis of HCV
infection have enhanced efforts to find a rapid, simple, sensitive,
and specific alternative diagnostic approach to detect viral
antigens. Similar to the detection of Hepatitis B Virus (HBV)
surface antigen for the diagnosis of HBV infection, the ZE2 DNA
aptamer may be helpful for the diagnosis of early HCV infection
through a simple ELISA method to detect HCV E2 envelope
Figure 2. Selected aptamers specifically bind to HCV E2. (A) SDS-PAGE (Left) and western blot analysis (Right) of the purified GST-E2 and GST
recombinant proteins. (B) Capillary electrophoresis analysis of single aptamer ZE2 binding to different doses of GST-E2 protein. Representative results
of CEMSA showed that the binding peak of ZE2 with GST-E2 migrated from left to right, but the binding peak of ZE2 with GST had no change.
doi:10.1371/journal.pone.0008142.g002
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PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8142Figure 3. The characterization of aptamer ZE2 specificity for E2-expressing cells. (A) Prediction of ZE2 secondary structure. Arrows
represent exchanged bases in ZE2-mut compared to that of the ZE2 aptamer. (B) Fluorescence microscope imaging of E2-expressing cells with FITC-
ZE2. FITC-ZE2 bound to E2-HepG2 cells but not to HepG2 cells by confocal immunofluorescence microscopy. (C) Comparison of different doses of
FITC-ZE2 or FITC-ZE2-mut binding to the E2-HepG2 or HepG2 cells by confocal immunofluorescence microscopy.
doi:10.1371/journal.pone.0008142.g003
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sequence hypervariable regions (HVR) but most of the E2
residues, the chemicophysical properties and conformation of
HVR are highly conserved [26]. CD81 is a conserved receptor for
HCV E2 binding. The DNA aptamer ZE2 and CD81 share
similar binding sites on HCV E2 (Fig. 5). Therefore, the DNA
aptamer ZE2 holds great potential for the detection of HCV
surface antigen in both clinical applications and basic research.
Based on genetic differences between HCV isolates, HCV has
been classified into six genotypes (through 1–6) with several
subtypes within each genotype (represented by letters) [27]. The
preponderance and distribution of HCV genotypes varies globally.
For example, in North America, genotype 1a predominates
followed by 1b, 2a, 2b, and 3a. In Europe, genotype 1b is
predominant followed by 2a, 2b, 2c, and 3a. Genotypes 4 and 5
are found almost exclusively in Africa [28]. The most common
genotypes of HCV in China and Korea are subtypes 1b and 2a,
followed by 1a or 6 [29,30]. Genotype is clinically important in
determining the potential patient response to interferon-based
therapy and the required duration of such therapy. Our results
showed that genotypes 1a, 1b, and 2a of E2 could be significantly
captured by aptamer ZE2, and the binding affinities of aptamer
ZE2 with genotypes 1a, 1b, and 2a of E2 were two-fold higher
than those of genotypes 3, 4, 5, and 6 (Fig. 4D). Our experiments
suggest that ZE2 can detect HCV particles in the sera of Chinese
patients (Table 3). ZE2 may also hold great potential for use in
the early diagnosis of HCV in Korea, the Americas, Europe,
and Japan, and could also be helpful in determining the
Figure 4. The ssDNA aptamer ZE2 specifically targets HCV particles. (A) HCVcc could be captured by the aptamer ZE2 in an aptamer dose-
dependent manner by sandwich ELISA. Plates were coated with anti-E2 polyclonal antibody and blocked with 1% BSA. After extensive washing, the
bound viral particles were added and then revealed using biotin-labeled aptamer ZE2, ZE3 or ZE2-mut as described in Materials and Methods. Data
shown were calculated as mean6SEM, and data are from three independent experiments. (B) Comparison of HCV detection methods: HCV E2
antigen-aptamer method and HCV RNA quantification by real time fluorescence quantitative RT-PCR. The aptamer method was performed as above
(A), except HCV patients and healthy donor serum samples were added into each 96-well ELISA plate instead of HCVcc. (C) Determination of E2
protein expressions of different genotypes of E1E2 gene stable-expressing HepG2 cells with anti-E2 antibody by western blot analysis. HepG2 was
uesd as a control. (D) Different genotypes of E2 detected by aptamer ZE2. Data shown were calculated as mean6SEM and data are from three
independent experiments.
doi:10.1371/journal.pone.0008142.g004
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prognostics.
Finally, we found that the DNA aptamer ZE2 could partially
block HCV E2 binding to the CD81 receptor (Fig. 5F) and
subsequent viral entry and infection of human hepatocytes (Fig. 6).
These data suggest that DNA aptamer ZE2 may also hold potential
for useas a drug against HCVinfection, whichis strengthened by its
low immunogenicity and ease of chemical synthesis in large
quantities at a relatively low cost. An anti-VEGF therapeutic
aptamer was the first approved by the FDA for macular
degeneration [31]. A second aptamer targeting the coagulation
factor IXa is currently being tested as an anticoagulant in phase I/II
clinical trials [32]. The newly selected aptamers, especially ZE2, are
worthy of further clinical and basic research.
In summary, our data demonstrate that the selected aptamers,
especially ZE2, hold great promise for developing new molecular
probes as early diagnostic reagents or therapeutic drugs targeting
HCV. Aptamers can also serve as tools for analyzing HCV-host cell
interactions both in vitro and in vivo. The experimental strategy
described in this study should be applicable for developing agonistic
aptamers targeting a broad range of cell surface-expressed envelope
glycoproteins of other viruses. The approach described here thus
provides a new set of tools to screen early diagnostic reagents or
therapeutic drugs against human viral diseases.
Materials and Methods
Cells and plasmids
Murine colon carcinoma cell line CT26 cells [33] were cultured
in RPMI-1640 medium with 10% (v/v) fetal bovine serum
(Hyclone). Rabbit anti-E2 polyclonal antibody was prepared as in
our previous publication [33]. Human hepatocellular liver
carcinoma cells Huh-7.5.1 [34] and HepG2 [35] were used in
this study. HCV cell culture (HCVcc)-JFH-1 (2a) and Huh-7.5.1
cells were derived from Huh-7.5, which was kindly provided by
Wen-Zhe Ho from the University of Pennsylvania School of
Medicine [34]. Cloned E1E2 genes of HCV genotypes 1 through 6
in a pcDNA3 expression vector were kindly provided by Dr.
Jonathan K. Ball from the University of Nottingham [36]. E1E2
gene stable-expressing HepG2 cells, E2 (genotype 1a) surface-
expressing HepG2 (E2-HepG2), and CT26 (E2-CT26) stable cell
lines were established by G418 selection [33]. E. coli BL21(DE3)/
plysS and E. coli DH5a were used as described previously [37].
The bacteria were harvested by centrifugation at 13,0006g and
suspended in sterile PBS at the appropriate concentration.
Bacterial CFUs (colony forming units) were quantified from the
absorbance at 600 nm. The CD81 recombinant protein was
kindly provided by Dr. Zhongtian Qi of the Second Military
Medical University in China [38].
Serum samples
HCV serum samples or healthy serum samples were collected
from 2006 to 2008 in Zhongnan Hospital of Wuhan University,
Wuhan, China. The ethical approval for this study was obtained
from the Zhongnan Hospital Research Ethics Committee. Written
informed consents were obtained from all individuals.
Getting the aptamers by Cell Surface- SELEX (CS-SELEX)
The CS - SELEX procedures were primarily based on our
previous work [37,39]. The library construction was designed, and
random oligonucleotide templates were synthesized as a single-
stranded 88-mer with the following sequence: 59-GCGGAATTC-
TAATACGACTCACTATAGGGAACAGTCCGAGCC-N30-GG-
GTCAATGCGTCATA-39, where the central N30 represents
random oligonucleotides based on equal incorporation of A, G, C,
and T at each position [37,39]. The complementary strand was
synthesized using the DNA polymerase I Klenow fragment with
primer 1: 59-GCGGGATCCTATGACGCATTGACCC-39,w h e r e
the underlined portion represents a BamHI site. The initial dsDNA
random library was generated by PCR amplification using primer 1
and primer 2: 59-GCGGAATTCTAATACGACTCACTATAGG-
GAACAGT-39, which contains an EcoRI site (underlined) [37,39].
PCR reactions were performed as follows: a 100 ml of PCR mixture
contained 10 ml of 10x PCR buffer, 0.2 mM dNTPs, 0.5 mMe a c h
primer, 10 nM template, and 2.5 U Taq DNA polymerase. The
mixture was thermally cycled 30 times through 95uCf o r1m i n ,3 7 uC
for 30 s, and 58uC for 40 s, followed by a 5 min extension at 58uC.
The ssDNA random library was then obtained by heating the dsDNA
library at 85uC for 15 min and snap-cooling on ice for 3 min.
To initiate in vitro selection, random ssDNAs were incubated in
binding buffer (25 mM Tris–HCl, 50 mM KCl, 200 mM NaCl,
0.2 mM EDTA, 5% (v/v) glycerol, and 0.5 mM DTT) for 30 min
at 37uC, together with 10
6 E2-CT26 cells. Following a wash with
at least 40 column volumes of binding buffer, bound ssDNA was
centrifuged at 12,000 rpm for 5 min, and the supernatant was
discarded. The precipitant was diluted by adding 50 mL sterile
ddH2O, boiled for 5 min, snap-cooled on ice for 3 min, extracted
by phenol/chloroform (25:24), and the supernatant was used as
the template for PCR to obtain the ssDNA pool for the next round
of selection. To remove nonspecifically bound DNA, we applied
the counter-selection step using CT26 cells followed by the
selection of E2-CT26 cells in each cycle. Each pool of aptamers
was obtained by a different round of selection. The PCR products
Table 3. Comparison of HCV E2 antigen-aptamer ZE2 assay and assays for HCV RNA quantities or HCV antibody detection.
Characteristic Healthy individuals (N=155) HCV patients (N=154) p-Value
Age-yr 41.1611.2 45.5613.4 0.85
Male sex-no. (%) 75(80) 76(78) 0.83
Race or ethnic group-no. (%) Asian 155 (100) 154 (100) 1.00
Region-no. (%) Hubei province, China 155 (100) 154 (100) 1.00
Anti-HCV-positive-no. (S/CO)(%) ,1 (0) .1 (100) ,0.001
HCV RNA –IU/ml (%) ,50 (0) .500 (100) ,0.001
OD450 (ZE2 binding for HCV) 0.0460.005 0.1360.06 ,0.05
Cutoff value (CO.)=0.1x mean OD450 of positive samples + mean OD450 of negative controls.
Anti-HCV-positive: OD450 of sample .CO., or S (Sample)/CO .1, anti-HCV-negative: OD450 of sample ,CO., or S/CO,1.
doi:10.1371/journal.pone.0008142.t003
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subcloned into pUC19. The bank was transformed into E. coli
DH5a. Plasmid DNA was isolated from individual clones, purified,
and analyzed by sequencing. Individual aptamers were
obtained.
Flow cytometry analysis
FITC-labeled aptamer pools or individual aptamers were
obtained by PCR using FITC-labeled primers. Individual
aptamers could also be synthesized according to their sequence.
To demonstrate the binding specificity and characterize the
Figure 5. DNA aptamer ZE2 and viral receptor CD81 share similar binding sites on HCV E2. (A) CD81 molecules are expressed on the
cellular surface of hepatocytes Huh7.5.1; flow cytometric analysis with PE-labeled anti-CD81 antibody. PE-conjugated rat IgG1 was used as an isotype-
matched control antibody (Ab). (B) HCV E2 had a much higher binding affinity for Huh7.5.1 than CT26 cells by flow cytometric analysis. E2-GST or GST
proteins were preincubated with 1610
6 Huh7.5.1 or CT26 cells, respectively. Anti-GST antibody and FITC-anti-IgG were added and analyzed by flow
cytometric analysis. (C) Different pools of aptamers or single DNA aptamer ZE2 can block HCV E2 protein binding to Huh7.5.1 cells. (D) GST and ZE2
do not bind to huh7.5.1 cells by flow cytometric analysis. (E) CD81 competitively blocked FITC-aptamer binding to E2-CT26 cells by flow cytometric
analysis. (F) Both ZE2 and CD81 competitively blocked E2 binding to Huh7.5.1 cells, as determined by flow cytometry with FITC-conjugated anti-E2
antibody. All data are mean6SEM from six separate experiments.
doi:10.1371/journal.pone.0008142.g005
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labeled aptamers (250 nM) were incubated with 10
6 E2-HepG2
(or E2-CT26), or HepG2 (or CT26) cells at 37uC for 15 min. They
were then centrifuged at 2,000 rpm for 5 min, and the supernatant
was discarded. The stained cells were then analyzed in a Beckman
Coulter EPICS ALTRA II flow cytometer. The binding affinities
of the individual aptamers to E2 glycoprotein-expressing cells were
obtained by monitoring the mean fluorescence intensity of target
E2-expressing cells bound to the FITC-labeled aptamers using a
flow cytometer as described [40]. The concrete steps were the
same as the flow cytometry analysis. The equation Y=BmaxX/
(Kd+X) (Origin Pro 7.5) was used to calculate the target antigen-
binding equilibrium dissociation constant Kd, where Bmax is the
maximum percentage of fluorescence, Y is the mean percentage
fluorescence, and X is the molecule mol concentration.
To detect whether the selected aptamer, ZE2, and CD81 share
similar binding sites on the HCV E2 protein, 20 mgo f
recombinant CD81 proteins were incubated with 1610
6 E2-
CT26 cells and then incubated with FITC-labeled aptamers
(250 nM) at 37uC for 1 hr. The binding affinities between E2-
CT26 cells and FITC-labeled aptamers were analyzed using flow
cytometry. PE-, or FITC-conjugated rat IgG1 were used as an
isotype-matched control.
Capillary electrophoretic mobility shift assay (CEMSA)
GST-E2, or GST recombinant proteins were purified according
to our previous publication [33]. In the analysis of the interaction
between aptamers and E2 or GST proteins, CEMSA was
performed on a Beckman P/ACE 5000 system (Fullerton, CA,
USA). A series of mixtures with a fixed concentration of aptamers
(250 nM) and increasing concentrations of E2, GST, or E2-GST
recombinant proteins was prepared. The concentrations of the
proteins in the mixtures were 0, 0.151, 0.302, 0.453, 0.604, and
0.755 mM, respectively. The mixtures were allowed to remain at
Figure 6. Aptamer ZE2 dramatically blocks HCVcc infection of hepatocytes. (A) Immunofluorescent detection of intracellular HCV mean
fluorescence density (MFI) of HCVcc infected Huh-7.5.1 cells with anti-E2 antibody. The data shown were calculated as mean6SEM and data are from
three independent experiments. (B) Western blot analysis of intracellular E2 protein expressions of HCVcc infected Huh7.5.1 in the presence of ZE2 or
IFN-a with specific anti-E2 antibody; b-actin, a housekeeping gene with constant expression, was used as internal control. b-actin protein was
detected with specific anti- b-actin antibody. (C) Quantitation of intracellular HCV RNA was detected using real-time quantitative RT-PCR and
normalized to the levels of GAPDH mRNA. GAPDH, a housekeeping gene with constant mRNA expression, was used as internal control. The data
shown were calculated as mean6SEM and data are from three independent experiments.
doi:10.1371/journal.pone.0008142.g006
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pressure injection mode at 0.5 psi for 10 s.
Fluorescence microscope imaging of E2-expressing cells
bound with aptamers
The FITC-labeled aptamers (250 nM each) were incubated
with 10
5 E2-HepG2, or E2-CT26, or CT26 cells per well in 6-well
plates with a cover slide in each well at 4uC overnight in the dark.
The unbound aptamers in the supernatant were then discarded.
The cell–ssDNA complex sediment was washed three times with
PBS. Cells were then fixed with 4% paraformaldehyde and
permeabilized with buffers containing 0.5% Triton X-100, 0.1%
SDS, and 50 mmol/L Tris (pH 8.0). The fixed cells were stained
with 100 mg/ml of the DNA-binding dye Propidium Iodide (PI)
(Sigma) at room temperature for 5 min. The cells were washed
three times with PBS. Imaging of the cells on the cover slide was
performed with a confocal fluorescence microscope (Leica DM
RXA) under 488 nm exciting light (green for FITC and red for PI)
and visible light.
Enzyme-Linked Immunosorbent Assay (ELISA)
A sandwich ELISA was performed for the virus capture assays
using aptamers. The anti-E2 polyclonal antibody was coated into
each well of a 96-well plate at 4uC overnight. After washing, the
plates were blocked with 2% bovine serum albumin (BSA). After
washing with phosphate-buffered saline (PBS)-0.1%(w/v) Tween-
20 (PBST), 100 mL of the serum samples or HCVcc (4610
5 copies
virus in 180 ml per well) was added to each well and incubated at
37uC for 30 min. HCV serum samples or healthy serum samples
were collected from 2006 to 2008 (viral titer determined by real-
time quantitative RT-PCR; provided by Zhongnan Hospital,
Wuhan University, China). The plates were then washed, and the
biotin-labeled aptamer (100 mL; 250 nM) was aliquoted into each
well. After incubation at 37uC for 30 min, a 1:1000 dilution of
HRP-streptavidin was added and incubated at 37uC for 30 min.
Finally, the samples were developed with a substrate solution
containing o-phenylenediamine. The absorbance of each sample
was measured at 450 nm.
To analyze the binding affinities between the aptamers and the
E1E2 glycoproteins of different genotypes (genotypes 1 through 6),
96-well ELISA plates were pretreated by coating them with
100 mg/mL poly-L-lysine. After incubating at room temperature
(RT) for 1 hr, the solution was removed, and the plates were
rinsed with water and dried. Different genotypes of E1E2 gene
stable-expressing HepG2 cells were established by G418 selection
and coated in the 96-well plates. After washing, 100 mL of the
biotin-labeled aptamers (250 nM) was added to each well. The
same steps as described above were then followed.
Measurement of anti-HCV antibody in the serum
Each fresh plasma sample was tested with an HCV antibody
ELISA assay kit (KHB, Shanghai kehua Co. P. R. China), and
HCV-positive samples (a sample-to-cut-off ratio (S/CO) higher
than 1) were kept frozen until use.
Measurement of inhibitory effects of aptamers on HCVcc
infection by fluorescence microscopy analysis
JFH-1 HCVcc (JFH-1; 10 mL; 1610
5 copies of virus) was pre-
incubated with the different doses of ssDNA aptamers at 37uC for
1 hr and then added to the 96-well plates with Huh-7.5.1 cells
(4.5610
5/well) in DMEM with 10% FBS. After a 12 hr
incubation, the virus-containing supernatant was removed and
replaced by fresh media. Cells were incubated at 37uC for 72 hrs.
Cells were washed with PBS and fixed for 20 min at room
temperature in 4% paraformaldehyde. The cells were then washed
with PBS containing 0.2% BSA. Fluorescence-labeled anti-E2
antibody was added to the Huh7.5.1 cells, incubated for 4 h, and
washed with PBS three times. HCVcc-infected Huh7.5.1 cells
were detected and measured by fluorescence microscopy.
RNA quantification by real time fluorescence quantitative
RT-PCR
Huh7.5.1 cells were cultured in a 6-well plate at a concentration
of 5610
5 cells/well. Different concentrations of aptamers, aptamer
mutants, or 1610
4 IU IFN-a were added to the cells along with
6610
5 viral copies of JFH-1 HCVcc. The mixtures were incubated
at 37uC overnight. Cells were washed with DEPC-treated PBS to
remove HCVcc in the supernatant, and total RNA was extracted
from HCVcc-infected or non-infected Huh7.5.1 cells using Trizol
reagent (Invitrogen Life Technologies); the RNA was then reverse
transcribed using the First Strand cDNA synthesis kit (Fergment).
The HCV primers were designed based on the HCV sequence
(GenBank Accession # M67463) selected within the 59-noncoding
region (NCR) of the HCV genome according to our previous
method [34]. RNA was quantitated by the real-time reverse
transcription polymerase chain reaction (RT-PCR) using the
QuantiTect
TM SYBR Green PCR Handbook Kit (QIAGEN) with
the primers P1: 59-CGGGAGAGCCATAGTGGTCTGCG-39
(130,152 nt) and P2: 59-CTCGCAAGCACCCTATCAGG-
CAGTA-39 (287,311 nt) (i.e., specific for HCV), or the primers
GAPDH-F: 59–ACCACAGTCCATGCCATCAC–39 and
GAPDH-R: 59–TCCACCACCCTGTTGCTGTA–39 (i.e., spe-
cific for housekeeping gene GAPDH). The results were analyzed
using Rotogene 6.0 software.
Western blot analysis
Huh7.5.1 cells were cultured in a 6-well plate at a concentration
of 5610
5 cells/well. Different concentrations of aptamers, apta-
mer mutants, or 500 IU IFN-a were added to the cells along with
6610
5 viral copies of JFH-1 HCVcc. The mixture was incubated
at 37uC overnight, and cells were washed with PBS and lysed with
200 ml SDS-loading buffer. Samples were then boiled for 5 min
and loaded onto a 12% SDS-polyacrylamide gel. After electro-
phoresis, proteins were transferred to a PVDF membrane, and E2
protein was detected with a specific anti-E2 polyclonal antibody;
b-actin protein was detected with a specific anti-b-actin antibody.
Statistical analysis
Experimental data were analyzed by ANOVA or an unpaired
Student’s t test. P-values ,0.05 were considered statistically
significant.
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